[Featured Stock] Kyungdong Pharmaceutical Rises 16% on Success of Phase 3 Clinical Trial for Benign Prostatic Hyperplasia Combination Therapy
Kyungdong Pharmaceutical is showing strong performance following the news that it has successfully completed the domestic Phase 3 clinical trial of the improved combination drug for benign prostatic hyperplasia, KDF1905-2BO.
As of 10:34 AM on the 12th, Kyungdong Pharmaceutical is trading at 7,470 KRW, up 16.72% (1,070 KRW) from the previous trading day.
On the same day, Kyungdong Pharmaceutical announced that the domestic Phase 3 clinical trial of the improved combination drug for benign prostatic hyperplasia, ‘KDF1905-2BO,’ confirmed improvement in lower urinary tract symptoms.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
KDF1905-2BO is a combination drug that combines tamsulosin (KDF1905-R1), a representative alpha-blocker for benign prostatic hyperplasia, and mirabegron (KDF1905-R2), an ingredient for treating overactive bladder. Tamsulosin and mirabegron are representative drugs with a high prescription rate in the urological field.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
